Biocryst Pharmaceuticals Inc.recently announced the issuance of inducement grants to three newly-hired employees in the form of stock options and restricted stock units (RSUs), as outlined in their press release on March 05, 2024.These grants were given to the employees as an incentive to join the company and were made in accordance with Nasdaq Listing Rule 5635(c)(4).
The compensation committee of Biocryst’s board of directors granted a total of 16,050 stock options and 11,300 RSUs to the new employees, enabling them to purchase and own Biocryst common stock.These grants were effective from February 29, 2024, and are considered material inducements for the employees to enter into employment with the company.
Currently, Biocryst Pharmaceuticals Inc.’s share price stands at $5.51.This represents a 36.57% drop from the previous year.It’s important to note that the impact of inducement grants on the company’s shares cannot be directly determined from this information alone.However, the grants are expected to have a positive influence on employee motivation and commitment, ultimately contributing to the long-term growth and success of Biocryst Pharmaceuticals Inc.
Comments